Inactive Instrument

News Qiagen Nasdaq

Equities

NL0012169213

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

QIAGEN NV : Deutsche Bank reiterates its Buy rating	Apr. 16	ZD
QIAGEN N.V. to release results for Q1 2024 and hold webcast	Apr. 09	AQ
Qiagen N : launches new solution for screening of sexual assault forensic casework samples	Apr. 04	PU
QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Annual Meeting 2024	Apr. 03	AQ
Qiagen N.V. Strengthens Its Portfolio for Cancer Research, Showcases Latest Product Launches At AACR Annual Meeting 2024	Apr. 03	CI
Mybio Are the New Exclusive Partner for Qiagen in Ireland & Northern Ireland	Mar. 27	CI
QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration across healthcare system	Mar. 25	AQ
QIAGEN Introduces QIAstat-Dx Analyzer 2.0 with Remote Test Results Access, Enhancing Collaboration Across Healthcare System	Mar. 25	CI
Qiagen Teams Up With Physicians Association for Tuberculosis Screening Program	Mar. 18	MT
QIAGEN partners with International Panel Physicians Association to increase awareness of tuberculosis screening requirements	Mar. 18	AQ
Qiagen N : Virtual Exane Conference Investor Introduction	Mar. 11	PU
Qiagen N : TD Cowen Healthcare Conference March 5-6 Investor Introduction	Mar. 11	PU
QIAGEN announces Form 20-F annual report filing for 2023 results	Mar. 11	AQ
For the UK: QIAGEN Ltd statement about the Modern Slavery Act 2015 for 2024	Mar. 06	PU
Transcript : Qiagen N.V. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 02:10 PM	Mar. 05
QIAGEN NV : UBS reaffirms its Neutral rating	Mar. 01	ZD
QIAGEN launches AI-derived biomedical knowledge base to accelerate data-driven drug discovery	Feb. 27	AQ
QIAGEN earns ACT Label for new eco-friendlier QIAwave products and achieves first My Green Lab Platinum certification	Feb. 27	AQ
Qiagen N : Share buyback program initiated in 2024 2024 Federal-8937 Report of Organizational Actions Affecting Basis of Securities (SSBB)_RS signed	Feb. 20	PU
Morgan Stanley Upgrades Qiagen to Overweight From Equalweight, Adjusts Price Target to $49.48 From $51	Feb. 16	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

QIAGEN : In line Q4; routine business prospects remain intact

February 07, 2024 at 10:30 am EST